Contraindications for Renal Artery Stenting
Renal artery stenting should NOT be performed in patients who have not failed optimal medical therapy with 3 antihypertensive medications (including a diuretic) at maximally tolerated doses, or who lack both specific clinical criteria AND hemodynamically significant stenosis. 1
Absolute Contraindications
Based on the 2018 ACC/AHA/SCAI/SIR/SVM guidelines, renal artery stenting is contraindicated when:
Failure to Meet Clinical Criteria
The patient must have at least one of these clinical presentations 1:
- Resistant/accelerated/malignant hypertension despite 3 medications at maximal doses (one being a diuretic)
- Hypertension with medication intolerance
- Hypertension with unexplained unilateral small kidney
- Progressive chronic kidney disease with bilateral RAS, RAS to solitary kidney, or unilateral RAS
- Recurrent unexplained heart failure, flash pulmonary edema, or unstable angina
Failure to Meet Anatomic/Hemodynamic Criteria
The lesion must meet at least one of these criteria 1:
- ≥70% diameter stenosis (by visual or intravascular ultrasound)
- 50-69% stenosis WITH hemodynamic confirmation:
- Resting systolic gradient ≥20 mmHg OR mean gradient ≥10 mmHg
- Hyperemic systolic gradient ≥20 mmHg OR mean gradient ≥10 mmHg
- Fractional flow reserve <0.8 (with dopamine or papaverine)
Inadequate Medical Therapy Trial
Stenting is contraindicated if the patient has not been tried on optimal medical management first 1. This represents the most fundamental contraindication based on the CORAL trial findings, which showed no benefit of stenting over medical therapy in unselected patients.
Relative Contraindications
High-Risk Anatomic Features
While not explicitly stated as contraindications in guidelines, certain scenarios carry substantially increased complication risks:
Fibromuscular dysplasia (FMD): Stenting in FMD carries a 58% complication rate including in-stent restenosis, under-expansion, and total occlusion 2. Angioplasty alone is preferred; stenting should be reserved only for angioplasty complications or primary dissection.
Elevated resistive index (RI) >0.80: Some evidence suggests this predicts poor revascularization response 3, though this remains controversial and should not be used as an absolute contraindication 3.
Clinical Scenarios Suggesting Poor Benefit
- Mild stenosis (<50%) without hemodynamic significance
- Well-controlled hypertension on fewer than 3 medications
- Stable renal function without progressive decline
- Advanced chronic kidney disease with irreversible parenchymal damage (though not an absolute contraindication, benefit is questionable)
Critical Pitfalls to Avoid
Do not stent based on imaging alone: Both clinical AND anatomic criteria must be met simultaneously 1
Do not skip the medical therapy trial: The guideline explicitly requires failure of 3-drug regimen (including diuretic) at maximal tolerated doses before considering intervention 1
Do not use stenting as first-line in FMD: This carries unacceptably high complication rates; reserve for angioplasty failures only 2
Do not rely on duplex ultrasound thresholds alone: While PSV >200-300 cm/s and RAR >3.5 suggest stenosis 3, hemodynamic confirmation is required for borderline lesions (50-69% stenosis) 1
The Evidence Framework
The 2018 ACC/AHA guidelines 1 explicitly incorporate lessons from the CORAL trial, which showed no benefit of routine stenting. The paradigm has shifted from "stent if stenosis is present" to "stent only if medical therapy has definitively failed AND specific high-risk clinical features are present." More recent data 4 suggests benefit may exist in subgroups with severe hypertension, worsening kidney function, high antihypertensive burden, or flash pulmonary edema—precisely the populations specified in the guideline clinical criteria.
The bottom line: absence of both appropriate clinical indications AND failure of optimal medical therapy represents an absolute contraindication to renal artery stenting in contemporary practice.